Axio BioPharma is a contract development and manufacturing organization (CDMO) that utilizes AI to enhance the development and production of mammalian-expressed recombinant proteins. The company provides tailored development strategies and reliable manufacturing solutions to expedite the transition of biologics from research to clinical applications.
Funding
$220K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing and manufacturing mammalian-expressed recombinant proteins is often a time-consuming and resource-intensive process, hindering the rapid advancement of biologics from research to clinical applications. Traditional methods may lack the efficiency and scalability needed to meet the growing demand for novel therapeutics.
Solution
Axio BioPharma is a contract development and manufacturing organization (CDMO) that leverages artificial intelligence to optimize the development and production of mammalian-expressed recombinant proteins. The company offers tailored process development strategies and scalable manufacturing solutions designed to accelerate the transition of biologics from initial concept to clinical trials. Axio BioPharma's approach aims to improve efficiency, reduce development timelines, and enhance the overall quality of recombinant protein production. By integrating AI into its workflows, Axio BioPharma provides clients with robust and reliable manufacturing services to support their drug development pipelines.
Target Audience
Axio BioPharma primarily serves biotechnology and pharmaceutical companies, as well as research institutions, involved in the development and manufacturing of mammalian-expressed recombinant proteins.
Features
- Custom process development strategies for mammalian-expressed proteins
- Parallel antibody manufacturing for rapid protein production to support discovery efforts
- Reliable production of high-quality research-grade proteins
- GMP manufacturing services (starting in 2028)
- AI-enhanced techniques to optimize biologics manufacturing
- Robust and scalable process designs